The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1706
ISSUE1706
July 8, 2024
Drugs for Postmenopausal Osteoporosis
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Drugs for Postmenopausal Osteoporosis
July 8, 2024 (Issue: 1706)
Pharmacologic treatment is recommended for
postmenopausal women who have bone density
T-scores (standard deviations from normal mean
values in the spine, femoral neck, total hip, or distal
radius) of -2.5 or below, T-scores between -1.0 and
-2.5...more
- PM Camacho et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis – 2020 update. Endocr Pract 2020; 26(Suppl 1):1. doi:10.4158/gl-2020-0524suppl
- A Qaseem et al. Pharmacologic treatment of primary osteoporosis or low bone mass to prevent fractures in adults: a living clinical guideline from the American College of Physicians. Ann Intern Med 2023; 176:224. doi:10.7326/m22-1034
- ACOG Committee on Clinical Practice Guidelines-Gynecology. Management of postmenopausal osteoporosis: ACOG clinical practice guideline no. 2. Obstet Gynecol 2022; 139:698. doi:10.1097/aog.0000000000004730
- FRAX. Fracture risk assessment tool. Available at https://bit.ly/4c0LQHJ. Accessed June 18, 2024.
- US Preventive Services Task Force. Vitamin D, calcium, or combined supplementation for the primary prevention of fractures in community-dwelling adults: US Preventive Services Task Force recommendation statement. JAMA 2018; 319:1592. doi:10.1001/jama.2018.3185
- G Voulgaridou et al. Vitamin D and calcium in osteoporosis, and the role of bone turnover markers: a narrative review of recent data from RCTs. Diseases 2023; 11:29. doi:10.3390/diseases11010029
- M Bargagli et al. Calcium and vitamin D supplementation and their association with kidney stone disease: a narrative review. Nutrients 2021; 13:4363. doi:10.3390/nu13124363
- RL Prentice et al. Health risks and benefits from calcium and vitamin D supplementation: Women’s Health Initiative clinical trial and cohort study. Osteoporos Int 2013; 24:567. doi:10.1007/s00198-012-2224-2
- S-K Myung et al. Calcium supplements and risk of cardiovascular disease: a meta-analysis of clinical trials. Nutrients 2021; 13:368. doi:10.3390/nu13020368
- C Inderjeeth et al. Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis. Int J Womens Health 2014; 7:7. doi:10.2147/ijwh.s73944
- FDA Drug Safety Communication: New contraindication and updated warning on kidney impairment for Reclast (zoledronic acid). Available at https://bit.ly/3RLTAWb. Accessed June 20, 2024.
- AA Khan et al. Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the International Task Force on ONJ. J Clin Densitom 2017; 20:8. doi:10.1016/j.jocd.2016.09.005
- M Singh and GS Gonegandla. Bisphosphonate-induced osteonecrosis of the jaws (BIONJ). J Maxillofac Oral Surg 2020; 19:162. doi:10.1007/s12663-019-01211-2
- DM Black et al. Atypical femur fracture risk versus fragility fracture prevention with bisphosphonates. N Engl J Med 2020; 383:743. doi:10.1056/nejmoa1916525
- G Curfman. Fosamax fractures—justice has not been served. JAMA 2024; 331:1887. doi:10.1001/jama.2024.6077
- DM Black et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006; 296:2927. doi:10.1001/jama.296.24.2927
- MA Izano et al. Bisphosphonate treatment beyond 5 years and hip fracture risk in older women. JAMA Netw Open 2020; 3:e2025190. doi:10.1001/jamanetworkopen.2020.25190
- KA Thal et al. Denosumab versus bisphosphonates for reducing fractures in postmenopausal women with osteoporosis: a meta-analysis. J Am Board Fam Med 2023; 36:175. doi:10.3122/jabfm.2022.220099r1
- AB Pedersen et al. Comparison of risk of osteoporotic fracture in denosumab vs alendronate treatment within 3 years of initiation. JAMA Netw Open 2019; 2:e192416. doi:10.1001/jamanetworkopen.2019.2416
- JR Curtis et al. Comparative effectiveness of denosumab vs alendronate among postmenopausal women with osteoporosis. J Bone Miner Res 2024 May 16 (epub). doi:10.1093/jbmr/zjae079
- HG Bone et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 2017; 5:513. doi:10.1016/s2213-8587(17)30138-9
- HG Bone et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 2011; 96:972. doi:10.1210/jc.2010-1502
- WL Tay and Donovan Tay. Discontinuing denosumab: can it be done safely? A review of the literature. Endocrinol Metab 2022 (Seoul); 37:183. doi:10.3803/enm.2021.1369
- SR Cummings et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 2018; 33:190. doi:10.1002/jbmr.3337
- BZ Leder et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet 2015; 386:1147. doi:10.1016/s0140-6736(15)61120-5
- T Makunts et al. Variable association of atypical femur fracture and osteonecrosis of jaw with bisphosphonates and denosumab use: drug-safety surveillance study. medRxiv 2020 June 15 (preprint). doi:10.1101/2020.06.15.20132290
- In brief: Severe hypocalcemia with denosumab (Prolia) in chronic kidney disease. Med Lett Drugs Ther 2024; 66:40.
- JH Krege et al. Teriparatide and osteosarcoma risk: history, science, elimination of boxed warning, and other label updates. JBMR Plus 2022; 6:e10665. doi:10.1002/jbm4.10665
- DL Kendler et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2018; 391:230. doi:10.1016/s0140-6736(17)32137-2
- JS Finkelstein et al. Effects of teriparatide retreatment in osteoporotic men and women. J Clin Endocrinol Metab 2009; 94:2495. doi:10.1210/jc.2009-0154
- Abaloparatide (Tymlos) for postmenopausal osteoporosis. Med Lett Drugs Ther 2017; 59:97.
- PD Miller et al. Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: results from the ACTIVE phase 3 trial. Bone 2019; 120:137. doi:10.1016/j.bone.2018.10.015
- A Gilsenan et al. Teriparatide did not increase adult osteosarcoma incidence in a 15-year US postmarketing surveillance study. J Bone Miner Res 2021; 36:244. doi:10.1002/jbmr.4188
- PD Miller et al. Effect of abaloparatide vs. placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA 2016; 316:722. doi:10.1001/jama.2016.11136
- KE Ensrud et al. Effects of raloxifene on fracture risk in postmenopausal women: the raloxifene use for the heart trial. J Bone Miner Res 2008; 23:112. doi:10.1359/jbmr.070904
- A Gosset et al. Menopausal hormone therapy for the management of osteoporosis. Best Pract Res Clin Endocrinol Metab 2021; 35:101551. doi:10.1016/j.beem.2021.101551
- J Stevenson et al. Prevention and treatment of osteoporosis in women. Post Reprod Health 2023; 29:11. doi:10.1177/20533691221139902
- Conjugated estrogens/bazedoxifene (Duavee) for menopausal symptoms and prevention of osteoporosis. Med Lett Drugs Ther 2014; 56:33.
- JV Pinkerton et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab 2014; 99:E189. doi:10.1210/jc.2013-1707
- Romosozumab (Evenity) for postmenopausal osteoporosis. Med Lett Drugs Ther 2019; 61:83.
- D Shoback et al. Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society guideline update. J Clin Endocrinol Metab 2020; 105:587. doi:10.1210/clinem/dgaa048
- F Cosman et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 2016; 375:1532. doi:10.1056/nejmoa1607948
- KG Saag et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 2017; 377:1417. doi:10.1056/nejmoa1708322
- BL Langdahl et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 2017; 390:1585. doi:10.1016/s0140-6736(17)31613-6
- A Knopp-Sihota et al. Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and metaanalysis. Osteoporos Int 2012; 23:17. doi:10.1007/s00198-011-1676-0
- In brief: Cancer risk with salmon calcitonin. Med Lett Drugs Ther 2013; 55:29.
- G Wells et al. Does salmon calcitonin cause cancer? A review and meta-analysis. Osteoporos Int 2016; 27:13. doi:10.1007/s00198-015-3339-z
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Drugs for Postmenopausal Osteoporosis
Article code: 1706a
Article code: 1706a
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.